Peng Yue
Company: ReviR Therapeutics
Job title: Co-Founder & Chief Executive Officer
Seminars:
Accelerating Splicing Modulation Therapies for Neurodegeneration with the VoyagR Platform 11:00 am
• Finalizing development of a lead candidate targeting HTT and PMS1 splicing with support from CIRM for IND-enabling studies in Huntington’s disease to accelerate clinical readiness and unlock therapeutic potential • Accelerating preclinical development with refined single-molecule chemistry and new functional datasets to enhance compound validation and improve translational confidence in ReviR’s lead asset •…Read more
day: Conference Day One
Panel Discussion Increasing Chemical Diversity in RNA-Targeted Splice Modulator Small Molecules to Expand the Target Space & Address Previously Undruggable Diseases 1:00 pm
• How can expanding the target space beyond the common splice modulators unlock new opportunities for targeting novel disease areas • What strategies are enabling the design of chemically diverse scaffolds to overcome current limitations in the ligand design space • Are we overdependent on nonsense-mediated decay and can reducing this reliance drive broaden therapeutic…Read more
day: Conference Day One
Panel Discussion: Building Strategic Collaborations & Investment Pathways to Accelerate RNA-Targeted Drug Discovery Across Biotech & Pharma 9:00 am
• Discussing the importance of pharma-biotech-academic collaborations and what each sector can provide to successfully create RNA-targeted therapeutics • How are large pharma and biotech companies structuring risk-sharing partnerships to access innovation and accelerate RNA-targeted therapeutic pipelines • How can early-stage companies leverage academic collaborations, tool compound sharing and co development deals to validate targets…Read more
day: Conference Day Two